Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and ...

At Christmas people with Crohn’s disease and ­colitis can often be left at risk of a digestive flare-up as they are tempted ...

Shares of Teva Pharmaceutical Industries surged more than 23% on Tuesday afternoon, reaching levels not seen since December ...

Major Cause of Inflammatory Bowel Disease Discovered June 5, 2024 — Researchers have discovered a new biological pathway that is a principal driver of inflammatory bowel disease (IBD ...

Crohn’s disease (CD) is a chronic idiopathic inflammatory bowel disease, with a complex aetiology involving genetic, ...

Teva reported that the trial met its primary endpoints in ulcerative colitis and Crohn's disease, the most common forms of ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Inflammatory bowel disease (IBD) in older adults has become a global public health burden, according to a study published in ...

Inflammatory bowel disease (IBD) rose in older adults over the past three decades, a new study finds. The stark increase in ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most ...

Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could ...

"This collaboration demonstrates a commitment to ensuring that all passengers, no matter their health condition, are treated ...